TIDMDEST
RNS Number : 3005Q
Destiny Pharma PLC
17 October 2023
Destiny Pharma plc
("Destiny Pharma" or "the Company")
New publication shows XF-73 drug potent against 2,527
Staphylococcus isolates
Largest study of its kind to date demonstrates effectiveness of
XF-73 against all tested antibiotic resistant strains
Brighton, United Kingdom - 17 October 2023 - Destiny Pharma
(AIM: DEST), a clinical stage biotechnology company focused on the
development and commercialisation of novel medicines to prevent and
cure life threatening infections, today announces the publication
of new microbiological data on XF-73 (exeporfinium chloride), its
leading antibacterial drug, in Frontiers in Cellular and Infection
Microbiology.
The paper, 'Screening of the novel antimicrobial drug XF-73
against 2,527 Staphylococcus species clinical isolates' , examined
the efficacy of XF-73 against more than 2,500 Staphylococcus
isolates with wide geographical and clinical diversity. These
isolates f rom 33 countries across Europe, North America, South
America, Asia and Africa, encompass 16 different staphylococcal
species, including resistant strains taken from patient infections
such as skin and soft tissue infections, respiratory tract
infections and hospital-acquired pneumonia .
The screening of XF-73 against this wide range of isolates
yielded the following landmark findings:
-- XF-73 effective against all 2,527 isolates tested
-- XF-73 effective against all tested antibiotic resistance mechanisms
-- XF-73 effective against 840 MRSA (1) clinical isolates from around the world
-- XF-73 effective against S. epidermidis, S. saprophyticus, S.
haemolyticus, S.capitis, S. hominis and S. lugdunensis - all of
high clinical significance(2)
These critical findings support the urgency of XF-73 nasal's
late-stage development and need for its global regulatory approval.
XF--73 demonstrates exceptionally broad potency across a huge range
of Staphylococcus isolates, including antibiotic resistant strains,
with no resistance observed. This study demonstrates XF-73's global
effectiveness and reinforces the significant commercial
opportunity. Importantly it also demonstrates the potential of
XF-73 nasal to address the shortcomings of current standard of care
nasal antibiotics, which contribute to the global rise in
Staphylococcus aureus antibiotic resistance thereby limiting the
effectiveness of current infection reduction approaches.
Dr Bill Love, Chief Scientific Officer of Destiny Pharma said:
"This peer-reviewed publication demonstrates that XF-73 has
activity against all global staphylococcal strains tested that were
obtained from patients who had infection from these bacteria. This
landmark data set will support the approval process for this
breakthrough drug in our lead indication for the prevention of
postsurgical staphylococcal infection."
Chris Tovey, CEO of Destiny Pharma, added: "The World Health
Organisation has declared antimicrobial resistance to be one of the
top ten global public health threats facing humanity. These new
findings underscore the transformative potential of XF-73 nasal not
only to prevent post-surgical infection of a vast range of
staphylococcal strains but also, critically, to be effective
against all S. aureus tested antibiotic resistant strains. We look
forward to sharing further details on the importance of these
findings at our XF pipeline event later today."
References:
1.
https://www.doherty.edu.au/news-events/news/who-global-priority-pathogens-list-of-antibiotic-resistant-bacteria
2. Michels, R., Last, K., Becker, S. L., and Papan, C. (2021). Update on Coagulase-Negative Staphylococci-What the Clinician Should Know. Microorganisms 9, 830. doi: 10.3390/microorganisms9040830
- END -
For further information, please contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
Powerscourt Group
Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher
Ward
+44 (0) 20 7250 1446
Destiny@powerscourt-group.com
Cavendish Capital Markets Limited (Nominated Adviser and Joint
Broker)
Geoff Nash / George Dollemore, Corporate Finance
Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
About Destiny Pharma
Destiny Pharma is an innovative, clinical-stage biotechnology
company focused on the development and commercialisation of novel
medicines that can prevent life-threatening infections. The
company's drug development pipeline includes two late stage assets
NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.
difficile infection (CDI) recurrence which is the leading cause of
hospital acquired infection in the US, and XF-73 nasal gel, a
proprietary drug targeting the prevention of post-surgical
staphylococcal hospital infections including MRSA.
For further information on the company, please visit
www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCKZMMGLVKGFZM
(END) Dow Jones Newswires
October 17, 2023 02:00 ET (06:00 GMT)
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
